Trials / Completed
CompletedNCT00404274
A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers
An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Steady-State Warfarin When Co-administered With Repeat Doses of Casopitant [GW679769] in Healthy Adult Subjects.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 97 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
GW679769 may affect liver enzymes that metabolize warfarin. This study is designed to test the extent of the GW679769 affect on Warfarin levels in humans.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Casopitant (GW679769) oral tablets | Casopitant will be available in the dose strength of 20,30 or 50 mg |
| DRUG | Warfarin oral tablets | Warfarin will be available in the dose strength of 5 mg |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2007-03-18
- Completion
- 2007-03-18
- First posted
- 2006-11-28
- Last updated
- 2017-08-09
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00404274. Inclusion in this directory is not an endorsement.